Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 31Triple Negative Breast Neoplasms 19Neoplasm Metastasis 5Urinary Bladder Neoplasms 4Carcinoma, Transitional Cell 4Carcinoma, Non-Small-Cell Lung 4Brain Neoplasms 4Salivary Gland Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Glioblastoma 2Colorectal Neoplasms 2Advanced Breast Cancer 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urothelial Bladder Carcinoma 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm, Residual 1Muscle Invasive Bladder Urothelial Carcinoma 1Mouth Neoplasms 1Meningeal Carcinomatosis 1Lung Diseases 1Localized Muscle Invasive Bladder Urothelial Carcinoma 1

Interventions

Cisplatin 7Etoposide 6Amifostine 6Radiotherapy 5Drug Therapy 5Cyclophosphamide 5apatinib 4Methotrexate 4Filgrastim 4Cytarabine 4sodium thiosulfate 3Methylprednisolone 3Carboplatin 3pegfilgrastim 2glucarpidase 2etoposide phosphate 2Voriconazole 2Vincristine 2Social Determinants of Health 2Pyridoxine 2Nivolumab 2Gemcitabine 2Doxorubicin 2Docetaxel 2Chemotherapy, Adjuvant 2Capecitabine 2trastuzumab deruxtecan 1selinexor 1sargramostim 1sacituzumab govitecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Drug-Related Side Effects and Adverse Reactions × sacituzumab govitecan × Clear all
NCT07582887 2026-05-13

Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response

Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental

Recruiting
70 enrolled
Breast

Breast Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon ⚡